SCM
AVDL

Sarissa Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Sarissa Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-875,000
Closed -$15.7M – 17
2015
Q1 		$15.7M Buy
+875,000
New +$13.7M 3.32% 8

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Sarissa Capital Management's AVDL Position: Q2 2015 in Review

Sarissa Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2015, closing a stake of 875,000 shares — an estimated $15.7M sold.

Sarissa Capital Management first reported a position in AVDL in Q1 2015 and held it in 1 quarter. The position peaked at $15.7M in Q1 2015. 87 funds tracked by Wall St. Rank hold AVDL as of Q2 2015.

  • Sarissa Capital Management reported no remaining Avadel Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Sarissa Capital Management sold 875,000 Avadel Pharmaceuticals shares in Q2 2015, an estimated $15.7M.
  • Sarissa Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Sarissa Capital Management's Avadel Pharmaceuticals position peaked at $15.7M in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2015.

Based on Sarissa Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.